Tulane National Primate Research Center, Covington, Louisiana, United States of America.
PLoS One. 2007 Aug 8;2(8):e726. doi: 10.1371/journal.pone.0000726.
The CC-chemokines CCL3, CCL4 and CCL5 have been found to block the entry of CCR5-tropic HIV into host cells and to suppress the viral replication in vitro, but the in vivo role of endogenous CC-chemokines in HIV-1 infection is still incompletely understood.
METHODOLOGY/PRINCIPLE FINDINGS: In this study, the primate host CCL3, CCL4 and CCL5 gene expression was evaluated in response to simian-human immunodeficiency virus (SHIV) infection in rhesus macaque model. Five rhesus macaques were inoculated with CCR5-tropic SHIV(SF162P4). The mRNA levels of CCL3, CCL4 and CCL5 were measured by real-time PCR at post inoculation day (PID) 0, 7, 14, 21, 35, 56 and 180 in peripheral blood. In addition, a selected subset of samples from CXCR4-tropic SHIV(Ku1)-infected macaques was included with objective to compare the differences in CC-chemokine down-regulation caused by the two SHIVs. Gut-associated lymphoid tissues (GALT) collected from SHIV(SF162P4)-infected animals were also tested by flow cytometry and confocal microscopy to corroborate the gene expression results. Predictably, higher viral loads and CD4+ T cell losses were observed at PID 14 in macaques infected with SHIV(Ku1) than with SHIV(SF162P4). A decline in CC-chemokine gene expression was also found during primary (PID 7-21), but not chronic (PID 180) stage of infection.
It was determined that A) SHIV(SF162P4) down-regulated the CC-chemokine gene expression during acute stage of infection to a greater extent (p<0.05) than SHIV(Ku1), and B) such down-regulation was not paralleled with the CD4+ T cell depletion. Evaluation of CC-chemokine enhancing immunomodulators such as synthetic CpG-oligonucleotides could be explored in future HIV vaccine studies.
趋化因子 CCL3、CCL4 和 CCL5 已被发现可阻止 CCR5 嗜性 HIV 进入宿主细胞,并在体外抑制病毒复制,但内源性趋化因子在 HIV-1 感染中的体内作用仍不完全清楚。
方法/原理发现:在这项研究中,评估了灵长类动物宿主 CCL3、CCL4 和 CCL5 的基因表达,以响应恒河猴模型中的猴免疫缺陷病毒(SHIV)感染。五只恒河猴接种 CCR5 嗜性 SHIV(SF162P4)。在接种后第 0、7、14、21、35、56 和 180 天(PID)通过实时 PCR 测量外周血中的 CCL3、CCL4 和 CCL5 的 mRNA 水平。此外,还包括了一组来自 CXCR4 嗜性 SHIV(Ku1)感染的猕猴的选定样本,目的是比较两种 SHIV 引起的 CC-趋化因子下调的差异。还通过流式细胞术和共聚焦显微镜测试了来自 SHIV(SF162P4)感染动物的肠相关淋巴组织(GALT),以证实基因表达结果。可预测的是,感染 SHIV(Ku1)的猕猴在 PID 14 时观察到更高的病毒载量和 CD4+T 细胞丢失,而感染 SHIV(SF162P4)的猕猴则没有。在急性(PID 7-21)而不是慢性(PID 180)感染阶段也发现了 CC-趋化因子基因表达的下降。
确定了 A)SHIV(SF162P4)在感染急性期下调 CC-趋化因子基因表达的程度大于 SHIV(Ku1)(p<0.05),B)这种下调与 CD4+T 细胞耗竭不平行。在未来的 HIV 疫苗研究中,可以探索评估 CC-趋化因子增强免疫调节剂,如合成 CpG 寡核苷酸。